10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay (2023)

10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay

Combining tissue profiling with wholetranscriptome spatial analysis and high-plex protein co-detectionenables a deeper, more holistic understanding of tissueorganization

PLEASANTON, Calif., May 24, 2023/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader insingle cell and spatial biology, announced today the commercialavailability of a new Visium CytAssist Gene and Protein Expressionproduct to expand the breadth of the Visium CytAssist spatialanalysis capabilities.

"The continued expansion of our Visium platform is a testamentto the strength of our innovation engine and demonstratedleadership in spatial biology," said Michael Schnall-Levin, Founding Scientist andChief Technology Officer. "This launch complements our focus onmultiomic analysis and broader protein capabilities on all three ofour leading platforms, including single cell and in situanalysis."

Visium CytAssist Gene and Protein Expressionenablesresearchers to simultaneously produce highly multiplexed proteinand whole transcriptome RNA data mapped together from the sameformalin-fixed, paraffin-embedded (FFPE) tissue section at highspatial resolution. The Human Immune Cell Profiling Panel is anoptimized, pre-titrated solution that enables the detection of 31intracellular and extracellular proteins and includes isotypecontrols for in-line normalization.

Visium's unique morphology-first workflow allows for H&Estaining upstream of chemical treatments made to the tissuesection. This allows researchers to study the morphology of theirtissue on the same section they also use for deeper spatialmultiomic exploration, allowing for three dimensions of spatialanalysis on the exact same sample.

"We are excited to leverage the CytAssist Gene and ProteinExpression solution to generate more complete assessments ofprotein, RNA, and morphology together on each and every tissuesection," said Dr. David Gate,Assistant Professor of Neurology at Northwestern University. "Spatial transcriptomicswith immune cell profiling at the protein level is transforming ourunderstanding of complex biological processes in neurodegenerativedisease with great potential to provide new insights intoAlzheimer'sdisease pathology."

About CytAssist Gene and Protein Expression
VisiumCytAssist Gene and Protein Expression enables combined capture ofprotein and whole transcriptome gene expression simultaneously withhistological analysis in one experiment, from a single tissuesection, using a sequencing based readout. The new kit, which isexclusively available for use with Visium CytAssist, is nowshipping.

Visium CytAssist is a compact, benchtop system designed toenable the rapid transfer of transcriptomic probes from tissues onstandard microscope slides to Visium slides. The instrument,launched in 2022, streamlines the Visium workflow by allowingexpanded sample access, simplifying sample handling and improvingdata quality for spatial transcriptomic studies.

About 10x Genomics
10x Genomics is a life sciencetechnology company building products to interrogate, understand andmaster biology to advance human health. Our integrated solutionsinclude instruments, consumables and software for analyzingbiological systems at a resolution and scale that matches thecomplexity of biology. 10x Genomics products have been adopted byresearchers around the world including in all of the top 100 globalresearch institutions as ranked by Nature in 2021 based onpublications and all of the top 20 global pharmaceutical companiesby 2021 research and development spend and have been cited in over5,000 research papers on discoveries ranging from oncology toimmunology and neuroscience. Our patent portfolio comprises morethan 1,750 issued patents and patent applications.

Forward Looking Statements
This press release containsforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995 as contained in Section27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended, which are subjectto the "safe harbor" created by those sections. All statements,other than statements of historical facts, may be forward-lookingstatements. Forward-looking statements generally can be identifiedby the use of forward-looking terminology such as "may," "might,""will,""enable," "should," "expect," "plan," "anticipate," "could,""intend," "target," "project," "contemplate," "believe,""estimate," "predict," "potential," "would," "likely," "seek" or"continue" or the negatives of these terms or variations of them orsimilar terminology, but the absence of these words does not meanthat a statement is not forward-looking. These forward-lookingstatements include statements regarding 10x Genomics, Inc.'sexpectations regarding the continued expansion of our Visiumplatform and our product momentum and progress, including theperformance of Visium's unique morphology-first workflow. Thesestatements are based on management's current expectations,forecasts, beliefs, assumptions and information currently availableto management, and actual outcomes and results could differmaterially from these statements due to a number of factors. Thematerial risks and uncertainties that could affect 10x Genomics,Inc.'s financial and operating results and cause actual results todiffer materially from those indicated by the forward-lookingstatements made in this press release include those discussed underthe captions "Risk Factors" and "Management's Discussion andAnalysis of Financial Condition and Results of Operations" in thecompany's most recently-filed 10-K and elsewhere in the documents10x Genomics, Inc. files with the Securities and ExchangeCommission from time to time.

Although 10x Genomics, Inc. believes that the expectationsreflected in the forward-looking statements are reasonable, itcannot provide any assurance that these expectations will prove tobe correct nor can it guarantee that the future results, levels ofactivity, performance and events and circumstances reflected in theforward-looking statements will be achieved or occur. Theseforward-looking statements do not reflect the potential impact ofany future acquisitions, mergers, dispositions, joint ventures orinvestments 10x Genomics, Inc. may make. Further, suchforward-looking statements may not accurately or fully reflect thepotential impact of adverse geopolitical and macroeconomic events,difficulties selling in APAC, product capabilities and adoptionrates, international economic, political, legal, compliance, socialand business factors, such as the COVID-19 pandemic, inflation,supply chain that may have on the business, financial condition,results of operations and cash flows of 10x Genomics, Inc. Theforward-looking statements in this press release are based oninformation available to 10x Genomics, Inc. as of the date hereof,and 10x Genomics, Inc. disclaims any obligation to update anyforward-looking statements provided to reflect any change in ourexpectations or any change in events, conditions, or circumstanceson which any such statement is based, except as required by law.These forward-looking statements should not be relied upon asrepresenting 10x Genomics, Inc.'s views as of any date subsequentto the date of this press release.

Disclosure Information
10x Genomics, Inc. uses filingswith theSecurities and Exchange Commission, our website(www.10xgenomics.com), press releases, public conference calls,public webcasts andour social media accounts as means ofdisclosing material non-public information and for complying withour disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to downloadmultimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-visium-cytassist-gene-and-protein-expression-assay-301833960.html

SOURCE 10x Genomics, Inc.

Latest TXG Messages

10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay (6)

Share on Facebook Share on Twitter Share on Email

Loading Messages....

No posts yet, be the first!No TXG Message Board. Create One!See More Posts on TXG Message BoardSee More Message Board Posts

10x Genomics, Inc. News

Loading Messages....

`, data() { return {tabs: [] }; }, created() { this.tabs = this.$children; }, methods: { selectTab(selectedTab) { this.tabs.forEach(tab => { tab.isActive = (tab.name == selectedTab.name); }); } }});Vue.component('tab', { template: `

`, props: { name: { required: true }, selected: { default: false} }, data() { return { isActive: false }; }, computed: { href() { return '#' + this.name.toLowerCase().replace(/ /g, '-'); } }, mounted() { this.isActive = this.selected; }});Vue.component('newslist', { template: `

No News, be the first to add your company releases.

`, props: { source: { required: true }, rawarticles: { required: true }, limit: { default: 12 } }, methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){ return _.uniqBy(articles, "headline");} }, data() { return { loaded: false, articles: [] }; }, mounted() { this.processData(this.rawarticles); }});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Interactive Strength Inc. d\/b\/a FORME Launches European Expansion Plan by Focusing on Strategic Partnership with SIGNA Sports United","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjAyNg==","timestamp":1684934081,"date":"Wed May 24, 2023 ","time":"9:14 AM (16 hours ago)","isPromoted":true},{"headline":"Kaya Holdings, Inc.'s V.P. Bryan Arnold Among First Ten (10) State Licensed Psilocybin Facilitators in U.S.A.","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjAyNA==","timestamp":1684932494,"date":"Wed May 24, 2023 ","time":"8:48 AM (17 hours ago)","isPromoted":true},{"headline":"10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91153386\/10x-genomics-launches-visium-cytassist-gene-and-pr","source":"PR Newswire (US)","date":"Wed May 24, 2023 ","time":"4:05 PM (9 hours ago)","article_id":91153386,"source_id":"prnus"},{"headline":"Current Report Filing (8-k)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91097935\/current-report-filing-8-k","source":"Edgar (US Regulatory)","date":"Wed May 17, 2023 ","time":"5:29 PM (1 week ago)","article_id":91097935,"source_id":"edgar"},{"headline":"10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91096235\/10x-genomics-wins-permanent-injunction-against-nan","source":"PR Newswire (US)","date":"Wed May 17, 2023 ","time":"4:05 PM (1 week ago)","article_id":91096235,"source_id":"prnus"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91066309\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon May 15, 2023 ","time":"4:55 PM (1 week ago)","article_id":91066309,"source_id":"edgar"},{"headline":"Report of Proposed Sale of Securities (144)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91038325\/report-of-proposed-sale-of-securities-144","source":"Edgar (US Regulatory)","date":"Thu May 11, 2023 ","time":"5:36 PM (2 weeks ago)","article_id":91038325,"source_id":"edgar"},{"headline":"Quarterly Report (10-q)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90965792\/quarterly-report-10-q","source":"Edgar (US Regulatory)","date":"Thu May 04, 2023 ","time":"5:07 PM (3 weeks ago)","article_id":90965792,"source_id":"edgar"},{"headline":"10x Genomics Reports First Quarter 2023 Financial Results","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90948064\/10x-genomics-reports-first-quarter-2023-financial","source":"PR Newswire (US)","date":"Wed May 03, 2023 ","time":"4:05 PM (3 weeks ago)","article_id":90948064,"source_id":"prnus"},{"headline":"Additional Proxy Soliciting Materials (definitive) (defa14a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90905048\/additional-proxy-soliciting-materials-definitive-d","source":"Edgar (US Regulatory)","date":"Fri Apr 28, 2023 ","time":"4:55 PM (4 weeks ago)","article_id":90905048,"source_id":"edgar"},{"headline":"Proxy Statement (definitive) (def 14a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90904570\/proxy-statement-definitive-def-14a","source":"Edgar (US Regulatory)","date":"Fri Apr 28, 2023 ","time":"4:43 PM (4 weeks ago)","article_id":90904570,"source_id":"edgar"},{"headline":"10x Genomics to Present at the BofA Securities 2023 Healthcare Conference","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90852334\/10x-genomics-to-present-at-the-bofa-securities-202","source":"PR Newswire (US)","date":"Tue Apr 25, 2023 ","time":"4:06 PM (4 weeks ago)","article_id":90852334,"source_id":"prnus"}],"All News": [{"headline":"Interactive Strength Inc. d\/b\/a FORME Launches European Expansion Plan by Focusing on Strategic Partnership with SIGNA Sports United","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjAyNg==","timestamp":1684934081,"date":"Wed May 24, 2023 ","time":"9:14 AM (16 hours ago)","isPromoted":true},{"headline":"Kaya Holdings, Inc.'s V.P. Bryan Arnold Among First Ten (10) State Licensed Psilocybin Facilitators in U.S.A.","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjAyNA==","timestamp":1684932494,"date":"Wed May 24, 2023 ","time":"8:48 AM (17 hours ago)","isPromoted":true},{"headline":"10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91153386\/10x-genomics-launches-visium-cytassist-gene-and-pr","source":"PR Newswire (US)","date":"Wed May 24, 2023 ","time":"4:05 PM (9 hours ago)","article_id":91153386,"source_id":"prnus"},{"headline":"Current Report Filing (8-k)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91097935\/current-report-filing-8-k","source":"Edgar (US Regulatory)","date":"Wed May 17, 2023 ","time":"5:29 PM (1 week ago)","article_id":91097935,"source_id":"edgar"},{"headline":"10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91096235\/10x-genomics-wins-permanent-injunction-against-nan","source":"PR Newswire (US)","date":"Wed May 17, 2023 ","time":"4:05 PM (1 week ago)","article_id":91096235,"source_id":"prnus"},{"headline":"Statement of Changes in Beneficial Ownership (4)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91066309\/statement-of-changes-in-beneficial-ownership-4","source":"Edgar (US Regulatory)","date":"Mon May 15, 2023 ","time":"4:55 PM (1 week ago)","article_id":91066309,"source_id":"edgar"},{"headline":"Report of Proposed Sale of Securities (144)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/91038325\/report-of-proposed-sale-of-securities-144","source":"Edgar (US Regulatory)","date":"Thu May 11, 2023 ","time":"5:36 PM (2 weeks ago)","article_id":91038325,"source_id":"edgar"},{"headline":"Quarterly Report (10-q)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90965792\/quarterly-report-10-q","source":"Edgar (US Regulatory)","date":"Thu May 04, 2023 ","time":"5:07 PM (3 weeks ago)","article_id":90965792,"source_id":"edgar"},{"headline":"10x Genomics Reports First Quarter 2023 Financial Results","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90948064\/10x-genomics-reports-first-quarter-2023-financial","source":"PR Newswire (US)","date":"Wed May 03, 2023 ","time":"4:05 PM (3 weeks ago)","article_id":90948064,"source_id":"prnus"},{"headline":"Additional Proxy Soliciting Materials (definitive) (defa14a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90905048\/additional-proxy-soliciting-materials-definitive-d","source":"Edgar (US Regulatory)","date":"Fri Apr 28, 2023 ","time":"4:55 PM (4 weeks ago)","article_id":90905048,"source_id":"edgar"},{"headline":"Proxy Statement (definitive) (def 14a)","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90904570\/proxy-statement-definitive-def-14a","source":"Edgar (US Regulatory)","date":"Fri Apr 28, 2023 ","time":"4:43 PM (4 weeks ago)","article_id":90904570,"source_id":"edgar"},{"headline":"10x Genomics to Present at the BofA Securities 2023 Healthcare Conference","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/10x-genomics-TXG\/stock-news\/90852334\/10x-genomics-to-present-at-the-bofa-securities-202","source":"PR Newswire (US)","date":"Tue Apr 25, 2023 ","time":"4:06 PM (4 weeks ago)","article_id":90852334,"source_id":"prnus"}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});

More 10x Genomics, Inc. News Articles